$0.57
2.55% yesterday
Nasdaq, May 20, 10:05 pm CET
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Lexicon Pharmaceuticals, Inc. Stock price

$0.57
-0.01 0.87% 1M
-0.24 29.40% 6M
-0.17 22.82% YTD
-1.20 67.80% 1Y
-1.20 67.80% 3Y
-1.46 71.92% 5Y
-6.50 91.94% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.01 2.55%
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Key metrics

Market capitalization $207.01m
Enterprise Value $118.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.79
P/S ratio (TTM) P/S ratio 6.63
P/B ratio (TTM) P/B ratio 1.68
Revenue growth (TTM) Revenue growth 1,250.63%
Revenue (TTM) Revenue $31.21m
EBIT (operating result TTM) EBIT $-168.56m
Free Cash Flow (TTM) Free Cash Flow $-169.77m
Cash position $194.84m
EPS (TTM) EPS $-0.51
P/E forward negative
P/S forward 46.13
EV/Sales forward 26.39
Short interest 28.69%
Show more

Is Lexicon Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Lexicon Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Lexicon Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
1,251% 1,251%
100%
- Direct Costs 1.18 1.18
69% 69%
4%
30 30
1,765% 1,765%
96%
- Selling and Administrative Expenses 114 114
10% 10%
366%
- Research and Development Expense 84 84
38% 38%
268%
-168 -168
9% 9%
-538%
- Depreciation and Amortization 0.57 0.57
3% 3%
2%
EBIT (Operating Income) EBIT -169 -169
9% 9%
-540%
Net Profit -177 -177
8% 8%
-568%

In millions USD.

Don't miss a Thing! We will send you all news about Lexicon Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexicon Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and  non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announc...
Neutral
Seeking Alpha
7 days ago
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conferen...
Neutral
GlobeNewsWire
7 days ago
Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE W...
More Lexicon Pharmaceuticals, Inc. News

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Michael Exton
Employees 103
Founded 1995
Website www.lexpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today